CLDX Stock — Celldex Therapeutics Inc.: Cash, EV, Pipeline

What they do

Celldex Therapeutics, Inc., which we refer to as “Celldex,” “we,” “us,” “our” or the “Company,” is a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases.

Source: 10-K FY2025 via SEC EDGAR

Share price

$28.84

Market cap

$2,265.2M

Cash

$650.3M

Enterprise value

$1,614.9M

Balance sheet

Cash	$650.3M
Debt	$0.0M
Net cash	$650.3M
Enterprise value	$1,614.9M
Basic shares	78.5M shares
Fully diluted shares	87.8M shares
Fully diluted market cap	$2,531.1M
Cash per share	$8.28
Quarterly burn	$57.4M
Cash runway	11.3 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-13.

Share structure

Common

78.5M

Pre-funded warrants

0.0M

Options

9.1M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.1M

FDSO

87.8M

Cap table as of 2026-06-30.

Price history

Loading CLDX daily closes…

Loading price history…

Next catalyst

barzolvolimab · Now - Dec 24, 2026 Now · Phase 3 · Chronic Spontaneous Urticaria

Recently reported

barzolvolimab Phase 3 Positive · 2026-09-22

EMBARQ-CSU1 · EMBARQ-CSU2 · chronic spontaneous urticaria

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Dec 24, 2026 Now	barzolvolimab	Phase 3	Chronic Spontaneous Urticaria	2027 Est. Jul 2, 2027 · guidance midpoint
Now - Dec 24, 2026 Now	barzolvolimab	Phase 3	Chronic Spontaneous Urticaria	—
Apr 12 - May 24 in 5 mo	CDX-622	Phase 1	Mild to Moderate Asthma	—
May 12 - Jun 23 in 6 mo	Human CMV pp65-LAMP mRNA-pulsed autologous DCs	Phase 2	Glioblastoma	—
Jul 13 - Aug 24 in 20 mo	Barzolvolimab	Phase 3	Chronic Inducible Urticaria; Cold Urticaria; Cold-Induced Urticaria	—
Oct 13 - Nov 24 in 23 mo	barzolvolimab	Phase 3	Chronic Spontaneous Urticaria	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Barzolvolimab

Phase 3 · Active Modality: humanized monoclonal antibody (subcutaneous)

Aliases CDX-0159

Target KIT

Indications

Chronic spontaneous urticaria (CSU) (Phase 3)
Chronic inducible urticaria (ColdU / symptomatic dermographism) (Phase 3)
Atopic dermatitis (Phase 2)

Catalysts

— September/October 2026
— late 2026

Status note CSU Phase 3 enrollment complete (1,939 pts); ColdU/SD Phase 3 initiated Dec 2025, enrolling. PN Phase 2 discontinued Jul 2026 after missing primary/key secondary endpoints (mast cells may not be key pathogenic driver in PN). $52.5M regulatory-approval milestone to former Kolltan holders on first FDA/EMA approval of a surviving product.

CDX-622

Phase 1 · Active Modality: bispecific antibody

Target TSLP / SCF

Indications

Asthma (mild-to-moderate) (Phase 1)

Status note First bispecific candidate (TSLP x SCF); Phase 1a in healthy volunteers (enrollment complete Jan 2026) plus open-label Phase 1 proof-of-mechanism study in mild-to-moderate asthma initiated Jan 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	barzolvolimab
Lead indication	Chronic Spontaneous Urticaria
Lead phase	Phase 3
Active trials	7
Collaborator trials	6

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06445023	Phase 3	Active, not recruiting	Sponsor	CLDX	—	Chronic Spontaneous Urticaria	2027 Est. Jul 2, 2027 · guidance midpoint
NCT06455202	Phase 3	Active, not recruiting	Sponsor	CLDX	—	Chronic Spontaneous Urticaria	—
NCT07266402	Phase 3	Recruiting	Sponsor	CLDX	—	Chronic Inducible Urticaria; Cold Urticaria; Cold-Induced Urticaria	—
NCT07256392	Phase 3	Enrolling by invitation	Sponsor	CLDX	—	Chronic Spontaneous Urticaria	—
NCT06366750	Phase 2	Active, not recruiting	Sponsor	CLDX	—	Prurigo Nodularis	—
NCT06727552	Phase 2	Active, not recruiting	Sponsor	CLDX	—	Atopic Dermatitis	—
NCT07330778	Phase 1	Recruiting	Sponsor	CLDX	—	Mild to Moderate Asthma	—
NCT03804944	Phase 2	Recruiting	Collaborator	Weill Medical College of Cornell University	MRK	Breast Cancer	—
NCT05231122	Phase 2	Recruiting	Collaborator	Roswell Park Cancer Institute	MRK	Ovarian Clear Cell Adenocarcinoma; Platinum-Sensitive Ovarian Carcinoma; Recurrent Endometrial Serous Adenocarcinoma	—
NCT03688178	Phase 2	Active, not recruiting	Collaborator	Annick Desjardins, MD	—	Glioblastoma	—
NCT05349890	Phase 1	Active, not recruiting	Collaborator	Providence Health & Services	—	Malignant Epithelial Neoplasms	—
NCT04930783	Phase 1	Active, not recruiting	Collaborator	Dana-Farber Cancer Institute	—	Melanoma; Metastatic Melanoma	—

Sponsor-matched active trials from ClinicalTrials.gov (7 as sponsor, 6 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 13 active trials for Celldex Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Logos Global Management	2,100,000	+1,650,000	3.36%	2026-08-14
Baker Bros. Advisors	1,182,611	+517,241	0.22%	2026-08-14
ADAR1 Capital Management	619,542	+191,726	1.08%	2026-08-14
Ikarian Capital	478,500	+17,253	2.91%	2026-08-14
Braidwell LP	436,646	-919,436	0.60%	2026-08-14
Sphera Biotech	240,868	-2,707	1.28%	2026-08-14
DAFNA Capital	68,518	no change	0.49%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CLDX — Celldex Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

CLDX — Celldex Therapeutics Inc.